肝がんの腫瘍内線維化を制御する新たな分子機構を解明~SPP1–CD44–Hedgehog 経路を標的とした線維化肝がんの新規治療戦略~

ad

2026-01-13 東京科学大学

東京科学大学の研究チームは、肝がんの進展に関わる「腫瘍内線維化」を促す新たな分子機構としてSPP1–CD44–Hedgehog/GLI1軸を解明した。372例の公開遺伝子発現データと103例の免疫染色解析から、線維化の強い肝がんで分泌タンパク質SPP1が高発現し、腫瘍径・門脈浸潤・線維化の程度と関連し、全生存・無再発生存が不良であることを示した。実験では肝がん細胞由来SPP1が肝星細胞のCD44を介してHedgehog経路を活性化し、肝星細胞の遊走・浸潤や線維化形成を促進、腫瘍増殖も増強することが確認された。Hedgehog阻害薬vismodegibは前臨床モデルで肝星細胞活性化、腫瘍内線維化、腫瘍増殖を抑制し、線維化を伴う肝がんに対する新たな分子標的治療戦略とバイオマーカー開発の可能性を示した。

肝がんの腫瘍内線維化を制御する新たな分子機構を解明~SPP1–CD44–Hedgehog 経路を標的とした線維化肝がんの新規治療戦略~
図1. SPP1遺伝子の同定と線維化、SPP1–CD44–Hedgehog シグナルの概要

<関連情報>

SPP1-CD44-ヘッジホッグ軸を標的とすることで、腫瘍内線維化を抑制し、肝細胞癌の治療効果を引き出す Targeting SPP1-CD44-Hedgehog Axis Elicits Therapeutic Effects in Hepatocellular Carcinoma by Suppressing Intratumoral Fibrosis

Atsushi Nara, Shu Shimada, Yoshimitsu Akiyama, Megumi Hatano, Yusuke Chino, Suguru Miyazawa, Hanako Tamura, Daisuke Asano, Yoshiya Ishikawa, Hiroki Ueda, Shuichi Watanabe …
Cancer Science  Published: 28 December 2025
DOI:https://doi.org/10.1111/cas.70296

ABSTRACT

Advanced hepatic fibrosis is a major risk factor for cirrhosis and hepatocellular carcinoma (HCC), and it is required to identify a key mediator involved in intratumoral fibrosis and HCC development. Transcriptomic analysis of 372 HCC samples using publicly available datasets revealed that SPP1 was significantly upregulated in fibrotic HCC tissues and associated with unfavorable outcomes. Immunohistochemical analysis of 103 HCC tissues and single-cell RNA sequencing (scRNA-seq) analysis of 228,564 live cells identified SPP1 overexpression in HCC cells, which strongly correlated with intratumoral fibrosis. In xenograft models, HCC cells with SPP1 overexpression (SPP1-OE) exhibited enhanced fibrosis and tumor growth. Coculture assay demonstrated that SPP1-OE cells stimulated hepatic stellate cells (HSCs), and gene set enrichment analysis and differential gene expression analysis elucidated the activation of the Hedgehog signaling pathway and upregulation of GLI1 in HSCs. Cell–cell interaction prediction analysis using scRNA-seq data suggested that SPP1-CD44 signaling transduction might contribute to HSC activation. Pharmacological inhibition of GLI1 with the SMO inhibitor vismodegib suppressed HSC activation in vitro and reduced fibrosis and tumor growth in vivo. These findings indicate that SPP1 promotes intratumoral fibrosis and HCC progression through the SPP1-CD44-GLI1 axis, highlighting its potential as a prognostic biomarker and therapeutic target. Inhibition of SPP1-CD44-Hedgehog signaling may provide a promising strategy to mitigate fibrosis and improve HCC patient outcomes.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました